At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection With the Proposed Merger With Tuhura Biosciences to Close on October 18, 2024
Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024
Kintara Therapeutics Announces Record Date for CVR Issuance in Connection With the Proposed Merger With Tuhura Biosciences Expected to Close on October 18, 2024
Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.